Sunitinib

87 interactions 9 explained in plain English

Also sold as: Sutent Sutent®

About Sunitinib

Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that were not treated successfully with imatinib (Gleevec) or people who cannot take imatinib. Sunitinib is… Read the full Sunitinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Colchicine Eribulin Injection Dasatinib Sertraline Oxaliplatin Injection

2 Contraindicated 84 Major 1 Moderate

All (87) Contraindicated (2) Major (84) Moderate (1)

Contraindicated

Sunitinib Colchicine Colcrys Explained Increased colchicine plasma concentrations and increased risk of toxicity Details Sunitinib Ketoconazole Topical Extina® Foam Increased exposure of SUNItinib and its active metabolite and an increased risk for QT interval prolongation Details

Major

Sunitinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Sunitinib Omeprazole Gastrobim Explained Reduction in sunitinib bioavailability Details Sunitinib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Sunitinib Sertraline Explained An increased risk of QT interval prolongation Details Sunitinib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Sunitinib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Sunitinib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Sunitinib Apixaban Eliquis Explained Increased apixaban exposure Details Sunitinib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Sunitinib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Sunitinib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Sunitinib Asciminib Scemblix Increased SUNItinib exposure and an increased risk of SUNItinib-related adverse effects Details Sunitinib Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation and an increased risk of torsade de pointes Details Sunitinib Azathioprine Azasan An increased risk of hepatotoxicity Details Sunitinib Azithromycin AzaSite An increased risk of QT interval prolongation Details Sunitinib Belumosudil Rezurock Explained Increased SUNItinib exposure Details Sunitinib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Sunitinib Anagrelide Agrylin Increased risk of QT interval prolongation Details Sunitinib Bedaquiline Sirturo Increased risk of QT interval prolongation Details Sunitinib Chloroquine Aralen® An increased risk of QT interval prolongation Details Sunitinib Dabigatran Pradaxa® Increased dabigatran etexilate exposure Details Sunitinib Dabigatran Etexilate Increased dabigatran etexilate exposure Details Sunitinib Dasatinib Phyrago An increased risk of QT interval prolongation Details Sunitinib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Sunitinib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Sunitinib Dexamethasone Injection Decadron Decreased plasma concentrations of sunitinib and its active metabolite Details Sunitinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased plasma concentrations of sunitinib and its active metabolite Details Sunitinib Dexlansoprazole Dexilant Reduction in sunitinib bioavailability Details Sunitinib Disopyramide Norpace An increased risk of QT interval prolongation Details Sunitinib Dofetilide Tikosyn An increased risk of QT interval prolongation Details Sunitinib Dolasetron Anzemet An increased risk of QT interval prolongation Details Sunitinib Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Sunitinib Edoxaban Savaysa Increased edoxaban exposure Details Sunitinib Enasidenib Idhifa Altered (increased/reduced) SUNItinib exposure and an increased risk of SUNItinib-related adverse effects or reduced efficacy of S... Details Sunitinib Encorafenib Braftovi Altered (increased or reduced) SUNItinib exposure; an increased risk of SUNItinib-related toxicities; reduced efficacy of SUNItini... Details Sunitinib Eribulin Injection Halaven Increased risk of QT interval prolongation Details Sunitinib Esomeprazole Nexium Reduction in sunitinib bioavailability Details Sunitinib Esomeprazole Injection Nexium Reduction in sunitinib bioavailability Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.